What alternative nicotine‑replacement or reduced‑harm products (e.g., Velo) can be used for smoking cessation to manage hypertension?

Alternative Nicotine Products for Smoking Cessation in Hypertension

Yes, nicotine pouches like Velo (oral nicotine pouches) can be used as an alternative for smoking cessation, though they are not FDA-approved smoking cessation medications and carry substantially less evidence than first-line therapies.

Understanding Velo vs. FDA-Approved Options

The "Velo" you're asking about appears to be nicotine pouches (oral tobacco-free nicotine products), which are completely different from the FDA drug "LUNSUMIO VELO" found in the evidence 1 - that's a cancer medication unrelated to smoking cessation.

Nicotine Pouches (Velo-type products)

• Risk profile: Approximately 2-3 orders of magnitude lower risk than cigarettes, approaching the safety of nicotine replacement therapy 2
• Not FDA-approved for smoking cessation
• Limited clinical trial data for cessation efficacy
• Deliver nicotine without combustion or vaporization

First-Line Recommendations for Smoking Cessation

The most effective evidence-based options are 3, 4:

1. Varenicline (OR 2.33) - 8 additional quitters per 100 people
2. Cytisine (OR 2.21) - 7 additional quitters per 100 people
3. Nicotine e-cigarettes (OR 2.37) - 8 additional quitters per 100 people
4. Combination NRT (patch + fast-acting form like gum/lozenge) (OR 1.93) - approximately 6 additional quitters per 100

Single NRT Products (less effective than combinations)

• Nicotine patch alone (OR 1.37) - 2 additional quitters per 100 4
• Fast-acting NRT alone (gum, lozenge, spray) (OR 1.41) - 3 additional quitters per 100 4
• Bupropion (OR 1.43) - 3 additional quitters per 100 4

E-Cigarettes as an Alternative

Nicotine e-cigarettes are highly effective and may be particularly beneficial for socially disadvantaged populations 5. In a 2025 randomized trial among people experiencing social disadvantage, e-cigarettes achieved 28.4% verified 6-month abstinence versus 9.6% with NRT - an 18.7% absolute difference 5. This represents one of the strongest effects seen in real-world populations.

E-cigarette Considerations

• Approximately 20 times less harmful than conventional cigarettes 2
• High-certainty evidence for effectiveness 4
• Fewer adverse events than NRT in some populations 5
• Concern: Continued nicotine dependence and unknown long-term cardiovascular effects 6
• Hypertension-specific data: Recent 2026 data suggests exclusive e-cigarette use (among former smokers who switched) may not increase hypertension risk, though this may reflect healthy switcher bias rather than protection 7

Cardiovascular Safety Profile

Critical caveat for hypertension patients: Nicotine itself has cardiovascular effects including increased blood pressure, heart rate, and potential contribution to coronary artery disease 6. However:

• Medicinal nicotine (NRT) has a good safety record when used as directed 6
• The harm from nicotine is substantially lower than the harm from other tobacco smoke constituents 6, 2
• No clear evidence of increased serious adverse events with NRT, varenicline, or cytisine 4
• Bupropion may slightly increase serious adverse events (moderate certainty) 4

Practical Algorithm for Product Selection

Step 1: Assess nicotine consumption

• 1 cigarette = 1-2 mg nicotine delivered
• 1 pack/day = at least 20 mg nicotine daily 3

Step 2: Choose based on patient preference and contraindications

• Most effective single agents: Varenicline, cytisine, or nicotine e-cigarettes
• If patient refuses medications: Combination NRT (patch for baseline + fast-acting for cravings)
• If patient specifically wants oral nicotine pouches: Can consider, but explain limited cessation evidence compared to FDA-approved options

Step 3: Dose adequately

• Common pitfall: Inadequate NRT dosing is a frequent cause of cessation failure 3
• Match nicotine replacement to consumption level
• For heavy smokers (>20 cigarettes/day): Use 21 mg patches plus fast-acting NRT as needed

Step 4: Duration

• Standard treatment: 12 weeks minimum 3
• Emerging evidence suggests longer treatment may improve success 3

Bottom Line on "Velo-type" Products

While nicotine pouches like Velo have a favorable safety profile compared to smoking 2, they lack the robust clinical trial evidence supporting varenicline, cytisine, e-cigarettes, or combination NRT for smoking cessation 4. If a patient is motivated to use oral nicotine products, FDA-approved nicotine lozenges or gum (fast-acting NRT) combined with patches would be the evidence-based choice 3, 4.

For hypertension specifically: All nicotine-containing products carry theoretical cardiovascular concerns 6, but the harm reduction benefit of stopping combustible tobacco far outweighs continued nicotine exposure through cleaner delivery systems 2.